nach oben

Erschienen in:

22.08.2022 | Original Paper

How useful is an oral calcium load test for diagnosing recurrent calcium stone formers?

verfasst von: Isabelle N. Tostivint, Vincent Castiglione, Rana Alkouri, Jean Philippe Bertocchio, Rachida Inaoui, Michel Daudon, Marie-Paule Dousseaux, Etienne Cavalier, Laurence Pieroni, Hassan Izzedine

Erschienen in: Urolithiasis | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Hypercalciuria is the main risk factor for recurrent calcium urolithiasis. The goal of our study is to determinate how useful an oral calcium load test is for stone formers to classify different forms of hypercalciuria in pathogenetic categories defined as renal or absorptive according to the current knowledge. Between June 2013 and February 2016, a prospective study was carried out on 117 documented recurrent hypercalciuric stone formers undergoing an oral calcium load test modified from the original description by Pak. After 2 days of calcium-restricted diet, urine and blood were analyzed at baseline and 120 min after receiving orally 1 g of calcium. Total and ionized calcium, parathyroid hormone from serum and urine calcium and creatinine were assessed in order to divide patients in three groups as previously described: resorptive, absorptive, and renal hypercalciuria. This allowed the identification of 19, 39, 34 and 33 patients with normocalcemic primary hyperparathyroidism (NPHPT), renal hypercalciuria aka renal calcium leak (RCL), absorptive hypercalciuria (AH) and unidentified cause, respectively. Patients with NPHPT (who required parathyroidectomy) experienced a lower PTH decrease (41.41 ± 12.82 vs. 54.06 ± 13.84% p < 0.01), higher beta-crosslaps, as well as lower TmP/GFR and distal third radius bone mineral density. RCL resulted in increased fasting urine calcium-to-creatinine ratio (Uca/Cr), i.e., > 0.37 mmol/mmol), without hyperparathyroidism. AH was diagnosed by the presence of ΔUCa/Cr > 0.60 mmol/mmol between baseline and 120 min without any other anomaly. For all remaining patients, results were inconclusive due to the lack of sufficient increase in serum calcium or because the cause of lithogenesis could not be clearly identified. The oral calcium load test is useful in nearly 80% of patients by identifying the different forms of hypercalciuria causing urolithiasis and by guiding treatment, including parathyroid surgery.

Knoll T, Schubert AB, Fahlenkamp D, Leusmann DB, Wendt-Nordahl G, Schubert G (2011) Urolithiasis through the ages: data on more than 200,000 urinary stone analyses. J Urol 185:1304–1311. https://doi.org/10.1016/j.juro.2010.11.073CrossRefPubMed

Daudon M, Bouzidi H, Bazin D (2010) Composition and morphology of phosphate stones and their relation with etiology. Urol Res 38:459–467. https://doi.org/10.1007/s00240-010-0320-3CrossRefPubMed

Leusmann DB, Niggemann H, Roth S, von Ahlen H (1995) Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol 29:279–283. https://doi.org/10.3109/00365599509180576CrossRefPubMed

Arrabal-Polo MA, Arrabal-Martin M, de Haro-Muñoz T, Poyatos-Andujar A, Palæo-Yago F, Zuluaga-Gomez A (2012) Biochemical determinants of severe lithogenic activity in patients with idiopathic calcium nephrolithiasis. Urology 79:48–54. https://doi.org/10.1016/j.urology.2011.07.1382CrossRefPubMed

Spivacow FR, del Valle EE, Negri AL, Fradinger E, Abib A, Rey P (2015) Biochemical diagnosis in 3040 kidney stone formers in Argentina. Urolithiasis 43:323–330. https://doi.org/10.1007/s00240-015-0778-0CrossRefPubMed

Healy KA, Hubosky SG, Bagley DH (2013) 24-hour urine collection in the metabolic evaluation of stone formers: is one study adequate? J Endourol 27:374–378. https://doi.org/10.1089/end.2012.0216CrossRefPubMed

Pak CY, Kaplan R, Bone H, Townsend J, Waters O (1975) A simple test for the diagnosis of absorptive, resorptive and renal hypercalciurias. N Engl J Med 292:497–500CrossRef

Pak CY, Sakhaee K, Pearle MS (2011) Detection of absorptive hypercalciuria type I without the oral calcium load test. J Urol 185:915–919. https://doi.org/10.1016/j.juro.2010.10.067CrossRefPubMed

Zhu X, Shan C, Zhu Q, Song L, Zhou Y, Liu J, Zhang K (2014) Clinical value of calcium load test in differential diagnosis of different types of hyperparathyroidism. Int J Clin Exp Med 7:5445–5452. eCollection 2014.

10.

Letavernier E, Traxer O, Daudon M, Tligui M, Hubert-Brierre J, Guerrot D, Sebag A, Baud L, Haymann JP (2011) Determinants of osteopenia in male renal-stone- disease patients with idiopathic hypercalciuria. Clin J Am Soc Nephrol 6:1149–1154. https://doi.org/10.2215/CJN.10191110CrossRefPubMedPubMedCentral

11.

Sadideen H, Swaminathan R (2004) Effect of acute oral calcium load on serum PTH and bone resorption in young healthy subjects: an overnight study. Eur J Clin Nutr 58:1661–1665. https://doi.org/10.1038/sj.ejcn.1602026CrossRefPubMed

12.

Maruani G, Hertig A, Paillard M, Houillier P (2003) Normocalcemic primary hyperparathyroidism: evidence for generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 88(10):4641–4648CrossRef

13.

Vargas-Poussou R, Mansour-Hendili L, Baron S, Bertocchio JP, Travers C, Simian C, Treard C, Baudouin V, Beltran S, Broux F, Camard O, Cloarec S, Cormier C, Debussche X, Dubosclard E, Eid C, Haymann JP, Kiando SR, Kuhn JM, Lefort G, Linglart A, Lucas-Pouliquen B, Macher MA, Maruani G, Ouzounian S, Polak M, Requeda E, Robier D, Silve C, Souberbielle JC, Tack I, Vezzosi D, Jeunemaitre X, Houillier P (2016) Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: similarities and differences. J Clin Endocrinol Metab 101(5):2185–2195CrossRef

14.

Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, Türk C (2015) Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol 67:750–763. https://doi.org/10.1016/j.eururo.2014.10.029CrossRefPubMed

15.

Taylor EN, Feskanich D, Paik JM, Curhan GC (2015) Nephrolithiasis and risk of incident bone fracture. J Urol 195:1482–1486. https://doi.org/10.1016/j.juro.2015.12.069CrossRefPubMedPubMedCentral

16.

Keller JJ, Lin CC, Kang JH, Lin HC (2013) Association between osteoporosis and urinary calculus: evidence from a population-based study. Osteoporos Int 24:651–657. https://doi.org/10.1007/s00198-012-2019-5CrossRefPubMed

17.

Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930. https://doi.org/10.1210/jc.2011-0385CrossRefPubMed

18.

Elkoushy MA, Sabbagh R, Unikowsky B, Andonian S (2012) Prevalence and metabolic abnormalities of vitamin D-inadequate patients presenting with urolithiasis to a tertiary stone clinic. Urology 79:781–785. https://doi.org/10.1016/j.urology.2011.09.004CrossRefPubMed

19.

Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470. https://doi.org/10.7326/0003-4819-130-6-199903160-00002CrossRefPubMed

20.

Payne RB (1998) Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 35:201–206. https://doi.org/10.1177/000456329803500203CrossRefPubMed

21.

Bouzidi H, de Brauwere D, Daudon M (2011) Does urinary stone composition and morphology help for prediction of primary hyperparathyroidism? Nephrol Dial Transplant 26:565–572. https://doi.org/10.1093/ndt/gfq433CrossRefPubMed

22.

Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F (2012) Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012:128352. https://doi.org/10.1155/2012/128352CrossRefPubMedPubMedCentral

23.

Tuna MM, Çalışkan M, Ünal M, Demirci T, Doğan BA, Küçükler K, Özbek M, Berker D, Delibaşı T, Güler S (2016) Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J Bone Miner Metab 34:331–335. https://doi.org/10.1007/s00774-015-0673-3CrossRefPubMed

24.

Monchik JM, Lamberton RP, Roth U (1992) Role of the oral calcium-loading test with measurement of intact parathyroid hormone in the diagnosis of symptomatic subtle primary hyperparathyroidism. Surgery 112:1103-9, discussion 1109-1110.

25.

Parks JH, Coe FL, Evan AP, Worcester EM (2009) Clinical and laboratory characteristics of calcium stone-formers with and without primary hyperparathyroidism. BJU Int 103:670–678. https://doi.org/10.1111/j.1464-410X.2008.08064.xCrossRefPubMed

26.

Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JEM, Rejnmark L, Thakker R, D’Amour P, Paul T, Van Uum S, Zakaria Shrayyef M, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Michael Lewiecki E, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Shawn Davison K, Potts JT Jr, Brandi ML, Bilezikian JP (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28:1–19. https://doi.org/10.1007/s00198-016-3716-2CrossRefPubMed

27.

Zhao L, Zhang M, Zhao H, Sun L, Li J, Tao B, Wang WQ, Ning G, Liu JM (2011) PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism. Clin Biochem 44:844–848. https://doi.org/10.1016/j.clinbiochem.2011.03.142CrossRefPubMed

28.

Hansen S, Jensen JEB, Rasmussen L, Hauge EM, Brixen K (2010) Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: A case-control study using HR-pQCT. J Bone Miner Res 25:1941–1947. https://doi.org/10.1002/jbmr.1540CrossRefPubMed

29.

Rowlands C, Zyada A, Zouwail S, Joshi H, Stechman MJ, Scott-Coombes DM (2013) Recurrent urolithiasis following parathyroidectomy for primary hyperparathyroidism. Ann R Coll Surg Engl 95:523–528CrossRef

30.

Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A, Cormier C (2014) Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 25:1963–1968. https://doi.org/10.1308/003588413X13629960048712CrossRefPubMed

31.

Bettinelli A, Viganò C, Provero MC, Barretta F, Albisetti A, Tedeschi S, Scicchitano B, Bianchetti MG (2014) Phosphate homeostasis in Bartter syndrome: a case-control study. Pediatr Nephrol 29:2133–2138. https://doi.org/10.1007/s00467-014-2846-zCrossRefPubMed

32.

Stechman MJ, Loh NY, Thakker RV (2009) Genetic causes of hypercalciuric nephrolithiasis. Pediatr Nephrol 24:2321–2332. https://doi.org/10.1007/s00467-008-0807-0CrossRefPubMed

33.

Reilly RF, Peixoto AJ, Desir GV (2010) The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. Clin J Am Soc Nephrol 5:1893–1903. https://doi.org/10.2215/CJN.04670510CrossRefPubMed

34.

Maalouf NM, Tondapu P, Guth ES, Livingston EH, Sakhaee K (2010) Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery. J Urol 183:1026–1030. https://doi.org/10.1016/j.juro.2009.11.022CrossRefPubMedPubMedCentral

35.

Arrabal-Polo MA, Arrabal-Martin M, Poyatos-Andujar A, Cardenas-Grande E, Merino-Salas S, Zuluaga-Gomez A (2012) Is the fasting calcium/creatinine a bone resorption marker in patients with calcium renal stones? Urol Res 40:243–245. https://doi.org/10.1007/s00240-011-0441-3CrossRefPubMed

36.

Pak CYC, Pearle MS, Sakhaee K (2011) Evidence for metabolic origin of absorptive hypercalciuria Type II. Urol Res 39:147–152. https://doi.org/10.1007/s00240-010-0315-0CrossRefPubMed

37.

Vezzoli G, Macrina L, Rubinacci A, Spotti D, Arcidiacono T (2016) Intestinal calcium absorption among hypercalciuric patients with or without calcium kidney stones. Clin J Am Soc Nephrol 11:1450–1455. https://doi.org/10.2215/CJN.10360915CrossRefPubMedPubMedCentral

38.

Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ (2013) Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 190:552–557. https://doi.org/10.1016/j.juro.2013.02.3188CrossRefPubMed

39.

Jüppner H (2010) Genetic disorders of renal phosphate transport. N Engl J Med 363(1774):1774–1775. https://doi.org/10.1074/jbc.M110.198416CrossRef

40.

Gunes S, Bilen CY, Kara N, Asci R, Bagci H, Yilmaz AF (2006) Vitamin D receptor gene polymorphisms in patients with urolithiasis. Urol Res 34:47–52. https://doi.org/10.1007/s00240-005-0033-1CrossRefPubMed

41.

Walton RJ, Bijvoet OL (1975) Nomogram for derivation of renal threshold phosphate concentration. Lancet (London, England) 2:309–310. https://doi.org/10.1016/s0140-6736(75)92736-1CrossRef

42.

Pak CY, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD (2003) Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. J Urol 169:465–469. https://doi.org/10.1097/01.ju.0000047341.55340.19CrossRefPubMed

43.

Heller HJ, Zerwekh JE, Gottschalk FA, Pak CY (2007) Reduced bone formation and relatively increased bone resorption in absorptive hypercalciuria. Kidney Int 71:808–815. https://doi.org/10.1038/sj.ki.5002181CrossRefPubMed

44.

Vezzoli G, Rubinacci A, Bianchin C, Arcidiacono T, Giambona S, Mignogna G, Fochesato E, Terranegra A, Cusi D, Soldati L (2003) Intestinal calcium absorption is associated with bone mass in stone-forming women with idiopathic hypercalciuria. Am J Kidney Dis 42:1177–1183. https://doi.org/10.1053/j.ajkd.2003.08.018CrossRefPubMed

45.

Guillemant J, Guillemant S (1996) Acute PTH response to oral calcium load and seasonal variation of vitamin D status in healthy young adult subjects. Eur J Clin Nutr 50:469–472PubMed

46.

Gupta A, Gupta N, Singh N, Goswami R (2010) Presence of impaired intestinal calcium absorption in chronic hypovitaminosis D and its change after cholecalciferol supplementation: Assessment by the calcium load test. J Hum Nutr Diet 23:54–60. https://doi.org/10.1111/j.1365-277X.2009.01003.xCrossRefPubMed

47.

Gomes SA, Lage A, Lazaretti-Castro M, Vieira JGH, Heilberg IP (2004) Response to an oral calcium load in nephrolithiasis patients with fluctuating parathyroid hormone and ionized calcium levels. Brazilian J Med Biol Res 37:1379–1388. https://doi.org/10.1590/s0100-879x2004000900013CrossRef

Titel: How useful is an oral calcium load test for diagnosing recurrent calcium stone formers?
verfasst von: Isabelle N. Tostivint
Vincent Castiglione
Rana Alkouri
Jean Philippe Bertocchio
Rachida Inaoui
Michel Daudon
Marie-Paule Dousseaux
Etienne Cavalier
Laurence Pieroni
Hassan Izzedine
Publikationsdatum: 22.08.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Urolithiasis / Ausgabe 5/2022
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-022-01355-w

Neu im Fachgebiet Urologie

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Complications and outcomes of tubeless versus nephrostomy tube in percutaneous nephrolithotomy: a systematic review and meta-analysis of randomized clinical trials

The combination of mean and maximum Hounsfield Unit allows more accurate prediction of uric acid stones

Contributions to expenditure in endoscopic stone management: a costly process

Extremely slow, half-number shockwave lithotripsy for ureteral stones